In what regulators called the latest advance in the development of personalized medicine the US Food and Drug Administration on Friday approved the first drug to treat cases of ovarian cancer linked to specific genetic mutations The drug made by AstraZeneca PLC was approved for women with defective genes known as BRCA and BRCA who have advanced ovarian cancer The mutations first discovered in the mids are linked to as many as  of all ovarian cancers and up to  of all breast cancers Last year actress
  